We work hard because you work harder. We build partnerships we can believe in. FAST is pleased to announce that GeneTx Biotherapeutics has been developing a potential ASO treatment for Angelman Syndrome. GeneTx is now partnering with Ultragenyx Pharmaceutical Inc. to ready this therapy for human clinical trials. Read more at Official Press Release #CureAngelman